These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 26386686)

  • 81. Pharmacotherapy of ulcerative colitis - current status and emerging trends.
    Ahmad H; Kumar VL
    J Basic Clin Physiol Pharmacol; 2018 Nov; 29(6):581-592. PubMed ID: 30089097
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Mucosal Healing in Ulcerative Colitis Patients Treated With Vedolizumab: Patient-, Dose-, or Duration-Dependent?
    Gaspar R; Liberal R; Macedo G
    J Crohns Colitis; 2017 Oct; 11(11):1403-1404. PubMed ID: 28531313
    [No Abstract]   [Full Text] [Related]  

  • 83. [Anti-TNF-alpha therapy in ulcerative colitis].
    Lakatos PL; Lakatos L
    Orv Hetil; 2008 May; 149(20):921-7. PubMed ID: 18467261
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
    Mohabbat AB; Sandborn WJ; Loftus EV; Wiesner RH; Bruining DH
    Aliment Pharmacol Ther; 2012 Sep; 36(6):569-74. PubMed ID: 22779779
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis.
    Dubinsky MC
    Postgrad Med; 2017 Jun; 129(5):538-553. PubMed ID: 28425825
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Response to vedolizumab for children with steroid-refractory Ulcerative Colitis unresponsive to anti-TNF.
    Wiskin AE; Paul SP; Spray CH
    Acta Paediatr; 2019 Jul; 108(7):1359-1360. PubMed ID: 30788859
    [No Abstract]   [Full Text] [Related]  

  • 87. Histologic remission: the ultimate therapeutic goal in ulcerative colitis?
    Peyrin-Biroulet L; Bressenot A; Kampman W
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):929-34.e2. PubMed ID: 23911875
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 89. First case report of exacerbated ulcerative colitis after anti-interleukin-6R salvage therapy.
    Atreya R; Billmeier U; Rath T; Mudter J; Vieth M; Neumann H; Neurath MF
    World J Gastroenterol; 2015 Dec; 21(45):12963-9. PubMed ID: 26668517
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
    Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
    Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to?
    Gearry RB; Irving PM
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1160-2. PubMed ID: 19682189
    [No Abstract]   [Full Text] [Related]  

  • 92. Etrolizumab for ulcerative colitis: the new kid on the block?
    Makker J; Hommes DW
    Expert Opin Biol Ther; 2016; 16(4):567-72. PubMed ID: 26914639
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Treatment of ulcerative colitis.
    Blonski W; Buchner AM; Lichtenstein GR
    Curr Opin Gastroenterol; 2014 Jan; 30(1):84-96. PubMed ID: 24285003
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Clinical and endoscopic efficacy of vedolizumab in patients with ulcerative colitis].
    Varvarynets AV; Chopei IV; Chubirko KI
    Wiad Lek; 2018; 71(2 pt 1):346-349. PubMed ID: 29729171
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Co-treatment With Golimumab and Vedolizumab to Treat Severe UC and Associated Spondyloarthropathy.
    Roblin X; Paul S; Ben-Horin S
    J Crohns Colitis; 2018 Feb; 12(3):379-380. PubMed ID: 29088342
    [No Abstract]   [Full Text] [Related]  

  • 96. Endoscopic surveillance in Crohn's disease and ulcerative colitis: who needs what and when?
    Baumgart DC
    Dig Dis; 2011; 29 Suppl 1():32-5. PubMed ID: 22104750
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Medical therapy versus surgery in moderate-to-severe ulcerative colitis.
    Fiorino G; Danese S; Giacobazzi G; Spinelli A
    Dig Liver Dis; 2021 Apr; 53(4):403-408. PubMed ID: 33051163
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Inflammatory bowel disease: A descriptive study of 716 local Chilean patients.
    Simian D; Fluxá D; Flores L; Lubascher J; Ibáñez P; Figueroa C; Kronberg U; Acuña R; Moreno M; Quera R
    World J Gastroenterol; 2016 Jun; 22(22):5267-75. PubMed ID: 27298570
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 100. An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab.
    Wyant T; Fedyk E; Abhyankar B
    J Crohns Colitis; 2016 Dec; 10(12):1437-1444. PubMed ID: 27252400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.